

10/553878

Atty. Docket No. PB60228USW

JC20 Rec'd PCT/PTO 17 OCT 2005
IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

IN RE: Application of Emmanuel Hubert DEMONT et al.

International Application No.: PCT/EPEP2004/004244

International Filing Date: April 21, 2004

For: TRYCYCLIC INDOLE DERIVATIVES AND THEIR USE IN THE TREATMENT OF ALZHEIMER'S DISEASE

Commissioner for Patents
P.O. Box 1450
Alexandria, VA 22313-1450

INFORMATION DISCLOSURE STATEMENT

Applicants request that the references identified on Form PTO-1449 appended hereto be considered by the Examiner and officially made of record in accordance with the provisions of 37 CFR 1.97

- [X] Copies of the references are enclosed
[] Copies of the references were submitted in parent application Serial No. _____.
(37 CFR 1.98(d))
[X] A copy of the International Search Report which issued on International Application No. PCT/EP2004/004244 is submitted herewith. All of the publications cited in the International Search Report are listed on the attached form PTO-1449 AS ITEMS 1-3 and Applicants understand that copies have been supplied to the U.S. Patent Office by the International Bureau.
- A. [X] The Information Disclosure Statement submitted herewith is being filed within three months of the filing date of the above application or date of entry into the national stage of an international application or before the mailing date of a first Office action on the merits, whichever event occurs last. 37 CFR 1.97(b).
OR
[] The Information Disclosure Statement submitted herewith is being filed before the mailing of a first office action after the filing of a Request For Continued Examination under 37 C.F.R. 1.114 (37 C.F.R. 1.97(b)(4)).
- B. [] The Information Disclosure Statement transmitted herewith is being filed after three months of the filing date of the above application or the date of entry into the national stage as set forth in § 1.491 of an international application or after the mailing date of the first Office Action on the merits, whichever event occurred last, but before the mailing date of either:
(1) a final action under § 1.113 or
(2) a notice of allowance under § 1.311,
whichever occurs first.

Express Mail Label No.: EV332065831US
Date of Mailing: 10/17/05

I hereby certify that this correspondence is being deposited with the United States Postal Service "Express Mail Post Office to Addressee" service under 37 CFR 1.10 in an envelope addressed to "Commissioner for Patents, P. O. Box 1450, Alexandria, VA 22313-1450 on the date shown above.

Patty Wilson
Patty Wilson

JG20 Recd PCTP 17 OCT 2003

- [] Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.
- [] Applicant elects the option to pay the fee set forth in 37 CFR 1.17(p) for submission of an Information Disclosure Statement under § 1.97(c) (\$180.00).
- C. [] The Information Disclosure Statement transmitted herewith is being filed **after** a final action under § 1.113, or a notice of allowance under § 1.311, whichever occurs first, but before the payment of the issue fee. Also enclosed is a copy of the International Search Report which Issued on International Publication No.


In accordance with the requirements of 37 CFR 1.97(d):

- [] Applicant hereby certifies that each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement. **[or]**
- [] Applicant hereby certifies that no item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application, and, to my knowledge after making reasonable inquiry, no item of information contained in this Information Disclosure Statement was known to any individual designated in § 1.56(c) more than three months prior to the filing of this statement; and
- [] The petition fee set forth in § 1.17(i)(1) (\$180.00) is submitted herewith.

[X] Please charge any required fees to Deposit Account No.07-1392.

[] A duplicate copy of this paper is attached.

Respectfully Submitted,


Bonnie L. Deppenbrock
Attorney of Record
Registration No. 28,209

Date: 13 October 2005

Customer No. 23347

GlaxoSmithKline

Corporate Intellectual Property

5 Moore Drive, P.O. Box 13398

Research Triangle Park, NC 27709-3398

Telephone: (919) 483-1577

Faxsimile: (919) 483-7988

FORM PTO-1449 INFORMATION DISCLOSURE STATEMENT		INT'L NO.	PCT/EP2004/004244
		INT'L FILING DATE	April 21, 2004
		APPLICANT	107523878 Dumont et al.
		GROUP	
		EXAMINER	
		ATTORNEY DOCKET NO.	PB60228USw

U.S. PATENT DOCUMENTS

Examiner Initials		Patent Number	Issue Date	Name	Class	Subclass	Filing Date If Appropriate
	1.	6,207,664	3/27/2001	Hayward et al.			

Continue on page

FOREIGN PATENT DOCUMENTS

		Document Number	Publication Date	Country	Class	Subclass	Translation Yes No
	2.	WO 02/02505	1/10/2002	PCT			
	3.	WO98/33795	8/6/1998	PCT			
	4.	WO01/70672	9/27/2001	PCT			
	5.	WO 02/02506	1/10/2002	PCT			
	6.	WO 02/02512	1/10/2002	PCT			

Continue on page

OTHER DOCUMENTS (Including Author, Title, Journal-Date, Page Number, Etc.)

7.	BERG et al., Acylation of 2,2,2,6,6-Tetramethylpiperidine and 2,2,5,5-Tetramethylpyrrolidine, J. Chem. Soc. C 1654-1658 (1971).
8.	BERGE et al., Pharmaceutical Salts, Journal of Pharmaceutical Sciences 66(1):1-19 (1977).
9.	CAI et al., BACE1 is the major β -secretase for generation of A β peptides by neurons, Nature Neuroscience 4(3):233-234 (2001).
10.	CONNOR, Cathepsin D, Handbook of Proteolytic Enzymes pp 828-836 (1998).
11.	Dalla Croce et al., Stereoselective synthesis of 3-heteroaromatic-substituted alanines, Tetrahedron: Asymmetry 11::2635-2642 (2000).
12.	DE STROOPER et al., A firm base for drug development, Nature 402:471-472 (1999).
13.	GREENE et al., The Role of Protective Groups in Organic Synthesis, Protective Groups in Organic Synthesis, 3 rd ed., 1-16 (1999).
14.	KERINS et al., Generation of Substituted Styrenes via Suzuki Cross-Coupling of Aryl Halides with 2,4,6-Trivinylcyclotriboroxane, J. Org. Chem. 67:4968-4971 (2002).
15.	LUO et al., Mice deficient in BACE1, the Alzheimer's β -secretase, have normal phenotype and abolished β -amyloid generation, Nature Neuroscience 4(3):231-232 (2001).
16.	NÄSLUND et al., Correlation Between Elevated Levels of Amyloid β -Peptide in the Brain and Cognitive Decline, JAMA 283(12):1571-1577 (2000).
17.	ROBERDS et al., BACE knockout mice are healthy despite lacking the primary β -secretase activity in brain: implications for Alzheimer's disease therapeutics, Human Molecular Genetics 10(12):1317-1324 (2001).
18.	SELKOE, Alzheimer's Disease: Genes, Proteins, and Therapy, Physiological Reviews 81(2):741-766 (2001).
19.	VASSAR et al., A β -Generating Enzymes: Recent Advances in β - and γ -Secretase Research, Neuron 27:419-422 (2000).
20.	YOUNKIN, Amyloid β vaccination: reduced plaques and improved cognition, Nature Medicine 7(1):18-19 (2001).

Continue on page

EXAMINER	DATE CONSIDERED
----------	-----------------

EXAMINER: Initial if citation considered, whether or not citation is in conformance with MPEP § 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to the applicant.